NCT00387972撤回2 期
A Multi-center, Double-blind, Parallel-group, Randomized, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Denagliptin in Subjects With Type 2 Diabetes Mellitus
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 撤回
- 试验地点
- 58
- 主要终点
- Change from baseline in blood glucose regulation after 26 weeks of treatment
研究概览
简要总结
GW823093 is a selective DPP-IV Inhibitor and is being investigated as a once a day oral therapy. The purpose of the Study is to evaluate the effectiveness, safety, and tolerability of 2 doses of GW823093, compared to placebo, taken once daily in patients with Type 2 diabetes mellitus.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
结局指标
主要结局
Change from baseline in blood glucose regulation after 26 weeks of treatment
次要结局
- Change from baseline in glycemic parameters, insulin, body weight and waist circumference, and safety measures
研究者
研究点 (58)
Loading locations...
相似试验
Unknown
2 期
GVD±R Regimen for ASCT-eligible Patients With Refractory/Relapsed DLBCLLymphoma, Large B-Cell, DiffuseNCT04021992Sun Yat-sen University48
已完成
3 期
Long Term Effects of DPP-IV Inhibitor Treatment in Patients With Type 2 DiabetesType 2 DiabetesNCT00411411University Hospital, Gentofte, Copenhagen49
已完成
2 期
A Study of the Effectiveness and Safety of SP2086 to Treat Type 2 DiabetesType 2 DiabetesNCT01969357Jiangsu HengRui Medicine Co., Ltd.200
已完成
3 期
Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 1)Chronic Hepatitis BHepatitis B, ChronicNCT05630807GlaxoSmithKline981
已完成
3 期
Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 2)Chronic Hepatitis BHepatitis B, ChronicNCT05630820GlaxoSmithKline857